Replies to post #245866 on Biotech Values

[DewDiligence]

FTC wants_more_time_to_review SNY-PRVB deal:

https://www.globenewswire.com/news-release/2023/04/10/2643960/0/en/Press-Release-Sanofi-announces-withdrawal-and-refiling-of-Premerger-Notification-and-Report-Form-under-the-HSR-Act-and-extension-of-tender-offer-to-acquire-Provention-Bio-Inc.html

I don’t see any deal-killing issues here; however, the FTC is taking nothing for granted when it comes to drug/biotech mergers.

[DewDiligence]

Physicians are unimpressed with SNY’s Tzield, according to market-research firm:

https://www.prnewswire.com/news-releases/less-than-half-of-endocrinologists-are-impressed-with-tzields-ability-to-delay-t1d-marketvue-report-301874485.html

SNY got Tzield in the $2,9B acquisition of PRVB (#msg-171430824).